Baseline characteristics of ASDAS ID and ASAS PR responders and non-responders at week 12 of open-label adalimumab treatment period
| Characteristic | ASDAS ID | ASAS PR | ||
| Responders (n=209) | Non-responders (n=384) | Responders (n=130) | Non-responders (n=466) | |
| Age (years) | 33.7±9.8 | 38.9±11.4*** | 32.0±8.7 | 38.5±11.3*** |
| Male, n (%) | 136 (65) | 156 (41)*** | 89 (68) | 206 (44)*** |
| Age >35 years, n (%) | 79 (38) | 215 (56)*** | 43 (33) | 252 (54)*** |
| Age >45 years, n (%) | 23 (11) | 113 (29)*** | 7 (5) | 129 (28)*** |
| Diagnosis duration, years | 1.7±2.9 | 1.8±3.6 | 1.7±3.0 | 1.8±3.2 |
| Symptom duration, years | 6.1±6.2 | 8.3±8.1*** | 5.3±5.7 | 8.0±7.8*** |
| HLA-B27 positive, n (%) | 181 (87) | 271 (71)*** | 116 (89) | 338 (73)*** |
| Concomitant DMARDs at baseline, n (%) | 46 (22) | 78 (20) | 33 (25) | 91 (20) |
| Concomitant NSAIDs at baseline, n (%) | 157 (75) | 271 (71) | 106 (82) | 325 (70)** |
| Concomitant corticosteroids at baseline, n (%) | 20 (10) | 54 (14) | 11 (8) | 63 (14) |
| ASDAS | 3.4±0.8 | 3.7±0.8*** | 3.7±0.9 | 3.6±0.8 |
| BASDAI | 6.6±1.3 | 7.1±1.4*** | 6.6±1.4 | 7.0±1.4** |
| Morning stiffness† | 6.9±1.8 | 7.0±2.0 | 6.9±1.9 | 7.0±1.9 |
| PGA | 6.3±1.5 | 6.7±1.5** | 6.4±1.5 | 6.6±1.5 |
| PtGA | 7.1±1.7 | 7.6±1.6*** | 7.1±1.7 | 7.5±1.6* |
| Total back pain | 7.0±1.7 | 7.7±1.5*** | 7.1±1.8 | 7.5±1.6** |
| hs-CRP | 9.1±13.1 | 10.9±16.8 | 15.6±21.5 | 8.8±13.2*** |
| Elevated hs-CRP (>ULN)‡, n (%) | 118 (56) | 260 (68)** | 87 (67) | 293 (63) |
| BASFI | 4.6±2.2 | 5.7±2.2*** | 4.9±2.4 | 5.4±2.2* |
| HAQ-S | 1.0±0.5 | 1.2±0.6*** | 1.0±0.6 | 1.2±0.6*** |
| SPARCC MRI SI joint score | 10.8±13.8 | 6.6±9.9*** | 13.9±15.8 | 6.6±9.7*** |
| SPARCC MRI spine score | 3.0±7.5 | 4.2±8.4 | 4.0±7.7 | 3.8±8.2 |
| MRI SI joint inflammation, n (%) | 164 (78) | 260 (68)** | 101 (78) | 326 (70) |
| MRI spine and/or SI joint inflammation, n (%) | 179 (86) | 291 (76)** | 109 (84) | 363 (78) |
Data are mean±SD unless otherwise indicated. Statistical significance for responders versus non-responders was assessed using t test for continuous variables and χ2 test for categorical variables.
*Indicates statistical significance at the 0.05 level, **Indicates statistical significance at the 0.01 level, ***Indicates statistical significance at the 0.001 level.
†Mean of BASDAI questions 5 and 6.
‡Elevated hs-CRP defined as >2.87 mg/L.
ASAS PR, Assessment of SpondyloArthritis international Society partial remission; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASDAS ID, ASDAS inactive disease; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; DMARD, disease-modifying antirheumatic drug; hs-CRP, high-sensitivity C reactive protein;HAQ-S, Health Assessment Questionnaire modified for the Spondyloarthropathies; HLA-B27, human leucocyte antigen B27; NSAID, non-steroidal anti-inflammatory drug; PGA, Physician Global Assessment of disease activity; PtGA, Patient Global Assessment of disease activity; SI, sacroiliac; SPARCC, Spondyloarthritis Research Consortium of Canada; ULN, upper limit of normal.